Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it failed to reach the primary endpoint in a Phase II trial. Preliminary ...

Sanofi has launched Dupixent for COPD in eight countries, said Hudson, who added that 2025 will be the "inflection year," for the treatment in the indication. Related ...

Sanofi backed its full-year guidance after higher first-quarter sales and profit that beat analysts' expectations. The French pharmaceutical company said Thursday that business operating profit ...

In a report released today, Emily Field from Barclays maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €125.00. The company’s shares closed yesterday at ...

Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma refocuses its relationship with Innate Pharma from oncology to ...

“I agree with the people in Massapequa, Long Island, who are fighting furiously to keep the Massapequa Chiefs logo on their Teams and School,” Trump posted on Truth Social on Monday.

Disclaimer: The views and investment tips by experts in this News18.com report are their own and not those of the website or its management. Users are advised to check with certified experts before ...

Ranjeet Mechatronics Split: Ranjeet Mechatronics is also set for Rs 10-to-Rs 5 stock split on April 21, 2025. Sanofi India Dividend: The pharma firm declared a final dividend of Rs 117 per equity ...

Regeneron and Sanofi are committed to helping patients in the U.S. who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT Dupixent has ...

Regeneron Pharmaceuticals and Sanofi won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent for the inflammatory skin condition chronic ...

April 18 (Reuters) - The U.S. Food and Drug Administration approved the use of Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a ...